SURMODICS INC(NASDAQ:SRDX) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to SRDX. SRDX was compared to 190 industry peers in the Health Care Equipment & Supplies industry. The financial health of SRDX is average, but there are quite some concerns on its profitability. SRDX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

SRDX had negative earnings in the past year.

In the past year SRDX had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: SRDX reported negative net income in multiple years.

SRDX had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -8.80%, SRDX is doing good in the industry, outperforming 61.17% of the companies in the same industry.

The Return On Equity of SRDX (-12.89%) is better than 63.30% of its industry peers.

		Industry Rank	Sector Rank
ROA	-8.8%
ROE	-12.89%
ROIC	N/A

ROA(3y)-8.18%

ROA(5y)-4.34%

ROE(3y)-12.06%

ROE(5y)-6.47%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 74.77%, SRDX belongs to the top of the industry, outperforming 86.17% of the companies in the same industry.

In the last couple of years the Gross Margin of SRDX has declined.

SRDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	74.77%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.3%

GM growth 5Y-3.08%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SRDX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, SRDX has more shares outstanding

SRDX has more shares outstanding than it did 5 years ago.

SRDX has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 7.53 indicates that SRDX is not in any danger for bankruptcy at the moment.

SRDX has a Altman-Z score of 7.53. This is amongst the best in the industry. SRDX outperforms 86.17% of its industry peers.

A Debt/Equity ratio of 0.26 indicates that SRDX is not too dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.26, SRDX is in line with its industry, outperforming 51.06% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	N/A
Altman-Z	7.53

ROIC/WACCN/A

WACC9.01%

2.3 Liquidity

A Current Ratio of 5.45 indicates that SRDX has no problem at all paying its short term obligations.

SRDX has a Current ratio of 5.45. This is in the better half of the industry: SRDX outperforms 79.26% of its industry peers.

A Quick Ratio of 4.29 indicates that SRDX has no problem at all paying its short term obligations.

SRDX's Quick ratio of 4.29 is fine compared to the rest of the industry. SRDX outperforms 77.66% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.45
Quick Ratio	4.29

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for SRDX have decreased strongly by -156.92% in the last year.

The Revenue has decreased by -9.23% in the past year.

SRDX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.72% yearly.

EPS 1Y (TTM)-156.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-360.26%

Revenue 1Y (TTM)-9.23%

Revenue growth 3Y6.25%

Revenue growth 5Y4.72%

Sales Q2Q%-2.06%

3.2 Future

SRDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 64.18% yearly.

Based on estimates for the next years, SRDX will show a small growth in Revenue. The Revenue will grow by 5.88% on average per year.

EPS Next Y-14.36%

EPS Next 2Y64.18%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year6.78%

Revenue Next 2Y5.88%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SRDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

A Price/Forward Earnings ratio of 151.85 indicates a quite expensive valuation of SRDX.

Compared to the rest of the industry, the Price/Forward Earnings ratio of SRDX indicates a somewhat cheap valuation: SRDX is cheaper than 65.96% of the companies listed in the same industry.

SRDX is valuated expensively when we compare the Price/Forward Earnings ratio to 22.68, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	151.85

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SRDX is valued a bit cheaper than 64.89% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	74.92

4.3 Compensation for Growth

A more expensive valuation may be justified as SRDX's earnings are expected to grow with 64.18% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y64.18%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SRDX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SURMODICS INC

NASDAQ:SRDX (2/21/2025, 8:00:00 PM)

After market: 34.85 0 (0%)

34.85

+0.47 (+1.37%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)01-30 2025-01-30/bmo

Earnings (Next)04-29 2025-04-29/bmo

Inst Owners86.57%

Inst Owner Change-94.66%

Ins Owners3.35%

Ins Owner Change-1.47%

Market Cap498.01M

Analysts47.5

Price Target43.86 (25.85%)

Short Float %4.38%

Short Ratio2.25

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)61.66%

Min EPS beat(2)56.65%

Max EPS beat(2)66.67%

EPS beat(4)4

Avg EPS beat(4)66.14%

Min EPS beat(4)19.79%

Max EPS beat(4)121.45%

EPS beat(8)8

Avg EPS beat(8)180.31%

EPS beat(12)12

Avg EPS beat(12)130.07%

EPS beat(16)15

Avg EPS beat(16)104.81%

Revenue beat(2)1

Avg Revenue beat(2)-2.45%

Min Revenue beat(2)-12.08%

Max Revenue beat(2)7.17%

Revenue beat(4)2

Avg Revenue beat(4)0.71%

Min Revenue beat(4)-12.08%

Max Revenue beat(4)8.62%

Revenue beat(8)6

Avg Revenue beat(8)5.82%

Revenue beat(12)9

Avg Revenue beat(12)4.75%

Revenue beat(16)12

Avg Revenue beat(16)3.66%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)-61.53%

EPS NQ rev (3m)-49.46%

EPS NY rev (1m)-54.17%

EPS NY rev (3m)21.44%

Revenue NQ rev (1m)-5.87%

Revenue NQ rev (3m)-5.15%

Revenue NY rev (1m)-6.4%

Revenue NY rev (3m)-6.4%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	151.85
P/S	3.97
P/FCF	N/A
P/OCF	434.56
P/B	4.46
P/tB	10.36
EV/EBITDA	74.92

EPS(TTM)-0.37

EYN/A

EPS(NY)0.23

Fwd EY0.66%

FCF(TTM)-0.13

FCFYN/A

OCF(TTM)0.08

OCFY0.23%

SpS8.78

BVpS7.82

TBVpS3.37

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-8.8%
ROE	-12.89%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	74.77%
FCFM	N/A

ROA(3y)-8.18%

ROA(5y)-4.34%

ROE(3y)-12.06%

ROE(5y)-6.47%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.3%

GM growth 5Y-3.08%

F-Score3

Asset Turnover0.77

Health

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	N/A
Debt/EBITDA	4.46
Cap/Depr	36.4%
Cap/Sales	2.45%
Interest Coverage	N/A
Cash Conversion	17.26%
Profit Quality	N/A
Current Ratio	5.45
Quick Ratio	4.29
Altman-Z	7.53

F-Score3

WACC9.01%

ROIC/WACCN/A

Cap/Depr(3y)37.09%

Cap/Depr(5y)48.03%

Cap/Sales(3y)2.78%

Cap/Sales(5y)3.64%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-156.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-360.26%

EPS Next Y-14.36%

EPS Next 2Y64.18%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-9.23%

Revenue growth 3Y6.25%

Revenue growth 5Y4.72%

Sales Q2Q%-2.06%

Revenue Next Year6.78%

Revenue Next 2Y5.88%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-113.52%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year237.43%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y92.15%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y105.46%

OCF growth 3Y-74.74%

OCF growth 5Y-50.13%

SURMODICS INC (SRDX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens